Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - Akari Therapeutics Plcv439186_ex31-1.htm
EX-31.2 - EXHIBIT 31.2 - Akari Therapeutics Plcv439186_ex31-2.htm
10-Q - FORM 10-Q - Akari Therapeutics Plcv439186_10q.htm

 

Exhibit 32.1

 

CERTIFICATIONS UNDER SECTION 906

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Akari Therapeutics, PLC, (the “Company”), does hereby certify, to such officer’s knowledge, that:

 

The Quarterly Report on Form 10-Q for the period ended March 31, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  Dated: May 12, 2016 /s/ Gur Roshwalb
    Chief Executive Officer
    (principal executive officer)
     
  Dated: May 12, 2016 /s/ Dov Elefant
    Dov Elefant
    Chief Financial Officer
    (principal accounting and financial officer)

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.